mRNA-4157 + Pembrolizumab for Cancer (KEYNOTE-603 Trial)
Trial Summary
The trial requires stopping certain medications before starting. You must not have taken investigational agents, certain cancer treatments, or live-virus vaccines within specific timeframes before the first dose. Check with the trial team for details on your specific medications.
Research shows that pembrolizumab, a part of the treatment, has been effective in improving survival rates in patients with advanced non-small cell lung cancer and metastatic melanoma. It has been approved by the FDA for these conditions due to its ability to prolong survival and provide durable responses.
12345Pembrolizumab (also known as Keytruda) has been used in various cancer treatments and is generally considered safe, but it can cause side effects like fatigue, cough, and nausea. Some serious immune-related side effects, such as pneumonitis (lung inflammation) and type 1 diabetes, have been reported in a small percentage of patients.
34678The combination of mRNA-4157 and Pembrolizumab is unique because it combines a personalized mRNA-based vaccine with an immune checkpoint inhibitor, Pembrolizumab, which blocks the PD-1 pathway to enhance the immune system's ability to fight cancer. This approach aims to boost the body's immune response specifically against cancer cells, offering a novel strategy compared to traditional treatments.
3891011Eligibility Criteria
Adults with certain unresectable solid tumors or those who are disease-free after resection can join. They must have measurable disease, not received prior PD-1/PD-L1 therapy (for some parts), and be suitable for pembrolizumab treatment. Participants need a tumor sample for sequencing and agree to use contraception.Inclusion Criteria
Participant Groups
- High-risk melanoma (adjuvant treatment)